Moderate to Severe Hot Flashes Without a Uterus: When Estrogen-Alone Therapy Has Not Achieved Adequate Relief

Clinical Scenario

This protocol applies to women experiencing moderate to severe hot flashes (vasomotor symptoms) who do not have a uterus — and in whom systemic estrogen-alone therapy, the established first-line approach, did not produce sufficient reduction of vasomotor symptoms.

Previous Treatment & Why It Was Insufficient

Systemic estrogen-alone therapy (ET) was the first-line treatment for this population. The target — meaningful reduction of hot flashes and night sweats — was not adequately met, making a next-line approach necessary.

Next-Line Approach (Partial Overview)

The structured protocol for this scenario centres on non-hormonal prescription medications drawn from several distinct drug classes. Which agents are considered, in what order, and under what clinical criteria is outlined in full in the complete protocol.

Clinical Goal

Meaningful reduction of moderate to severe vasomotor symptoms (hot flashes).

Instant Access to Structured Evidence-Based Regimens

References

Moderate to severe hot flashes: MHT is the gold standard and best therapy for reduction of VMS (Tables 1-5), followed by non-hormonal prescription medications (Tables 6, 7) as a second choice.

Women without a uterus can use systemic estrogen-alone therapy (ET).

For those with contraindications to hormone therapy or a desire to avoid it, SSRI/SNRIs, gabapentinoids, or clonidine may reduce VMS in some women.

View source ↗